After TORe for post-RYGB weight regain, the liraglutide-then-placebo group had greater percent total body-weight loss than placebo-then-liraglutide at month 12 while initially taking liraglutide.
In plain wordsAfter TORe for post-bypass weight regain, liraglutide-then-placebo had greater weight loss than placebo-then-liraglutide at month 12.
- Peptide
- Liraglutide
- Outcome
- IncreasePercent total body-weight-loss magnitude at month 12
- Study
n = 109
- Comparator
- Placebo-then-liraglutide sequence
- Analysis
- Primary
- Outcome group
- Body weight · Metabolic and weight
- Studied dose
- Dose not stated · subcutaneous · 12 monthsAs given in this study (human).
Source sentences
Group LP showed significantly higher %TBWL than group PL at 6, 9, and 12 months.
4 context sentences(design, population, supporting numbers)
Two cohorts were established: group placebo then liraglutide (group PL) received subcutaneous saline dosed daily for 12 months after TORe then liraglutide for the subsequent 12 months, while group liraglutide then placebo (group LP) started subcutaneous liraglutide followed by subcutaneous saline in a similar fashion.
The primary outcomes were percent total body weight loss (%TBWL) at 12 and 24 months.
The study comprised 58 participants in group PL and 51 participants in group LP, with no significant difference in mean baseline BMI between groups.
A Randomized, Double-Blind, Two-Way Cross-over Study to Evaluate the Efficacy of Liraglutide Treatment in Patients Undergoing Transoral Outlet Reduction Endoscopy for Weight Regain Post Roux-en-Y Gastric Bypass.